Abstract

Malaria is a devastating disease. It was the cause of 627,000 deaths worldwide in 2020, and malaria-related mortality has increased by more than 10% over the past 3 years. Although there are highly effective treatments, the development of multidrug-resistant strains poses a great threat to the control and elimination of malaria. Moreover, prevention is a better strategy than treatment. Despite several approaches to prevent established infection, no single approach offers complete protection, so a multilayered approach is needed. One potential layer, the monoclonal antibody [2] is the focus of a trial by Wu and colleagues¹ and the editorial by Daily² in this issue of the Journal. They describe protection conferred by a long-acting, next-generation monoclonal antibody against controlled human malaria infection in healthy persons.

To view the full article, please visit the New England Journal of Medicine website [3].